A Phase II Study Of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
This phase II clinical trial is studying how well dasatinib followed by stem cell transplant
works in treating older patients with newly diagnosed acute lymphoblastic leukemia.
Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer
cells by stopping them from dividing or killing them. Monoclonal antibodies, such as
alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer
cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Giving more than one drug (combination chemotherapy) and
giving dasatinib together with chemotherapy may kill more cancer cells.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.